Patents by Inventor Kathrin Ladetzki-Baehs
Kathrin Ladetzki-Baehs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240052042Abstract: The present disclosure relates to use of reversal agents which specifically bind to anti-Natriuretic Peptide Receptor 1 (NPR1) antibodies or antigen binding fragments thereof, and reverse one or more effects of the anti-NPR1 antibody or antigen binding fragments thereof (e.g., hypotensive effects).Type: ApplicationFiled: December 13, 2021Publication date: February 15, 2024Inventors: Yuichiro ADACHI, Jennifer R. ALLPORT-ANDERSON, Shaun R. COUGHLIN, John Louis DIENER, Lars GADTKE, Felix HARTLEPP, Tiancen HU, Alexander Wolfgang KOCH, Kathrin LADETZKI-BAEHS, Michael John ROMANOWSKI, Cesare RUSSO, Xenia Karola WEZLER, Xiaoling XIE
-
Publication number: 20230399381Abstract: The present invention provides synthetic canine antibody libraries, as well as polypeptides, nucleic acids, vectors, host cells and methods used in conjunction with these libraries. The present invention also provides antibodies isolated from such libraries.Type: ApplicationFiled: May 31, 2023Publication date: December 14, 2023Inventors: Thomas Tiller, Markus Waldhuber, Ralf Strohner, Kathrin Ladetzki-Baehs, Josef Prassler
-
Publication number: 20230365674Abstract: This disclosure relates to anti-Natriuretic Peptide Receptor 1 (NPR1) antibodies including agonist antibodies which are able to activate the NPR1 receptor, pharmaceutical compositions comprising the same, and methods of treatment comprising the same.Type: ApplicationFiled: March 30, 2023Publication date: November 16, 2023Inventors: John Louis DIENER, Lars GADTKE, Felix HARTLEPP, Tiancen HU, Kathrin LADETZKI-BAEHS, Michael John ROMANOWSKI, Cesare RUSSO, Xenia WEZLER, Xiaoling XIE
-
Patent number: 11702463Abstract: The present invention provides synthetic canine antibody libraries, as well as polypeptides, nucleic acids, vectors, host cells and methods used in conjunction with these libraries. The present invention also provides antibodies isolated from such libraries.Type: GrantFiled: April 22, 2021Date of Patent: July 18, 2023Assignee: MORPHOSYS AGInventors: Thomas Tiller, Markus Waldhuber, Ralf Strohner, Kathrin Ladetzki-Baehs, Josef Prassler
-
Publication number: 20220356242Abstract: This disclosure relates to anti-Natriuretic Peptide Receptor 1 (NPR1) antibodies including agonist antibodies which are able to activate the NPR1 receptor, pharmaceutical compositions comprising the same, and methods of treatment comprising the same.Type: ApplicationFiled: June 16, 2021Publication date: November 10, 2022Inventors: John Louis DIENER, Lars GADTKE, Felix HARTLEPP, Tiancen HU, Kathrin LADETZKI-BAEHS, Michael John ROMANOWSKI, Cesare RUSSO, Xenia WEZLER, Xiaoling XIE
-
Publication number: 20210317190Abstract: The present invention provides synthetic canine antibody libraries, as well as polypeptides, nucleic acids, vectors, host cells and methods used in conjunction with these libraries. The present invention also provides antibodies isolated from such libraries.Type: ApplicationFiled: April 22, 2021Publication date: October 14, 2021Inventors: Thomas Tiller, Markus Waldhuber, Ralf Strohner, Kathrin Ladetzki-Baehs, Josef Prassler
-
Patent number: 11066469Abstract: This disclosure relates to anti-Natriuretic Peptide Receptor 1 (NPR1) antibodies including agonist antibodies which are able to activate the NPR1 receptor, pharmaceutical compositions comprising the same, and methods of treatment comprising the same.Type: GrantFiled: June 10, 2020Date of Patent: July 20, 2021Assignee: NOVARTIS AGInventors: John Louis Diener, Lars Gadtke, Felix Hartlepp, Kathrin Ladetzki-Baehs, Michael Romanowski, Cesare Russo, Xenia Wezler
-
Patent number: 11014978Abstract: The present invention provides synthetic canine antibody libraries, as well as polypeptides, nucleic acids, vectors, host cells and methods used in conjunction with these libraries. The present invention also provides antibodies isolated from such libraries.Type: GrantFiled: June 21, 2018Date of Patent: May 25, 2021Assignee: MORPHOSYS AGInventors: Thomas Tiller, Markus Waldhuber, Ralf Strohner, Kathrin Ladetzki-Baehs, Josef Prassler
-
Publication number: 20200392225Abstract: This disclosure relates to anti-Natriuretic Peptide Receptor 1 (NPR1) antibodies including agonist antibodies which are able to activate the NPR1 receptor, pharmaceutical compositions comprising the same, and methods of treatment comprising the same.Type: ApplicationFiled: June 10, 2020Publication date: December 17, 2020Inventors: John Louis DIENER, Lars GADTKE, Felix HARTLEPP, Tiancen HU, Kathrin LADETZKI-BAEHS, Michael ROMANOWSKI, Cesare RUSSO, Xenia WEZLER, Xiaoling XIE
-
Publication number: 20200223904Abstract: The present invention provides synthetic canine antibody libraries, as well as polypeptides, nucleic acids, vectors, host cells and methods used in conjunction with these libraries. The present invention also provides antibodies isolated from such libraries.Type: ApplicationFiled: June 21, 2018Publication date: July 16, 2020Inventors: Thomas Tiller, Markus Waldhuber, Ralf Strohner, Kathrin Ladetzki-Baehs, Josef Prassler
-
Patent number: 10640568Abstract: The present disclosure provides isolated binding molecules that bind to human 4-1BB, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.Type: GrantFiled: March 6, 2018Date of Patent: May 5, 2020Assignee: Pfizer Inc.Inventors: Bianca Ahrens, Sangita M. Baxi, Timothy Scott Fisher, Richard Michael Jerome, Kathrin Ladetzki-Baehs, Theodore Lawrence Oliphant, Leslie Lynne Sharp, Michael Tesar, Libbey Anne Yates, Moritz Zulley
-
Publication number: 20180194851Abstract: The present disclosure provides isolated binding molecules that bind to human 4-1BB, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.Type: ApplicationFiled: March 6, 2018Publication date: July 12, 2018Applicant: Pfizer Inc.Inventors: Bianca AHRENS, Sangita M. BAXI, Timothy Scott FISHER, Richard Michael JEROME, Kathrin LADETZKI-BAEHS, Theodore Lawrence OLIPHANT, Leslie Lynne SHARP, Michael TESAR, Libbey Anne YATES, Moritz ZULLEY
-
Publication number: 20160369000Abstract: The present disclosure provides isolated binding molecules that bind to human 4-1BB, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.Type: ApplicationFiled: September 6, 2016Publication date: December 22, 2016Applicant: Pfizer Inc.Inventors: Bianca Ahrens, Sangita M. Baxi, Timothy Scott Fisher, Richard Michael Jerome, Kathrin Ladetzki-Baehs, Theodore Lawrence Oliphant, Leslie Lynne Sharp, Michael Tesar, Libbey Anne Yates, Moritz Zulley
-
Patent number: 9468678Abstract: The present disclosure provides isolated binding molecules that bind to human 4-1BB, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.Type: GrantFiled: May 13, 2014Date of Patent: October 18, 2016Assignee: Pfizer Inc.Inventors: Bianca Ahrens, Sangita M. Baxi, Timothy Scott Fisher, Richard Michael Jerome, Kathrin Ladetzki-Baehs, Theodore Oliphant, Leslie Lynne Sharp, Michael Tesar, Libbey Anne Yates, Moritz Zulley
-
Patent number: 9114131Abstract: An isolated antibody capable of binding Siglec-15 which inhibits osteoclast formation and/or osteoclastic bone resorption, or a functional fragment thereof. The heavy chain of the antibody comprises a CDRH1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 106, a CDRH2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 107, and a CDRH3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 35, 45, 55, 65 or 80. The light chain of the antibody comprises a CDRL1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 73 or 83, a CDRL2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 108, and a CDRL3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 40, 50, 60, 70, 90, 100 or 109.Type: GrantFiled: October 4, 2011Date of Patent: August 25, 2015Assignee: Daiichi Sankyo Company, LimitedInventors: Ichiro Watanabe, Yoshiharu Hiruma, Eisuke Tsuda, Tatsuji Matsuoka, Toshiaki Ohtsuka, Tohru Takahashi, Toshinori Agatsuma, Sandra Miller, Robert Mühlbacher, Kathrin-Ladetzki Baehs, Steffen Runz, Ulrike Schubert, Ingrid Schuster, Dirk Ponsel
-
Publication number: 20140377255Abstract: The present disclosure provides isolated binding molecules that bind to human 4-1BB, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.Type: ApplicationFiled: May 13, 2014Publication date: December 25, 2014Applicant: PFIZER INCInventors: Bianca Ahrens, Sangita M. Baxi, Timothy Scott Fisher, Richard Michael Jerome, Kathrin Ladetzki-Baehs, Theodore Oliphant, Leslie Lynne Sharp, Michael Tesar, Libbey Anne Yates, Moritz Zulley
-
Patent number: 8821867Abstract: The present disclosure provides isolated binding molecules that bind to human 4-1BB, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.Type: GrantFiled: November 14, 2012Date of Patent: September 2, 2014Assignee: Pfizer IncInventors: Bianca Ahrens, Sangita M. Baxi, Timothy Scott Fisher, Richard Michael Jerome, Kathrin Ladetzki-Baehs, Theodore Oliphant, Leslie Lynne Sharp, Michael Tesar, Libbey Anne Yates, Moritz Zulley
-
Publication number: 20130280276Abstract: An isolated antibody capable of binding Siglec-15 which inhibits osteoclast formation and/or osteoclastic bone resorption, or a functional fragment thereof. The heavy chain of the antibody comprises a CDRH1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 106, a CDRH2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 107, and a CDRH3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 35, 45, 55, 65 or 80. The light chain of the antibody comprises a CDRL1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 73 or 83, a CDRL2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 108, and a CDRL3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 40, 50, 60, 70, 90, 100 or 109.Type: ApplicationFiled: October 4, 2011Publication date: October 24, 2013Inventors: Ichiro Watanabe, Yoshiharu Hiruma, Eisuke Tsuda, Tatsuji Matsuoka, Toshiaki Ohtsuka, Tohru Takahashi, Toshinori Agatsuma, Sandra Miller, Robert Mühlbacher, Kathrin-Ladetzki Baehs, Steffen Runz, Ulrike Schubert, Ingrid Schuster, Dirk Ponsel
-
Patent number: 8337850Abstract: The present disclosure provides isolated binding molecules that bind to human 4-1BB, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.Type: GrantFiled: September 9, 2011Date of Patent: December 25, 2012Assignee: Pfizer Inc.Inventors: Bianca Ahrens, Sangita M. Baxi, Timothy Scott Fisher, Richard Michael Jerome, Kathrin Ladetzki-Baehs, Theodore Oliphant, Leslie Lynne Sharp, Michael Tesar, Libbey Anne Yates, Moritz Zulley
-
Publication number: 20120237498Abstract: The present disclosure provides isolated binding molecules that bind to human 4-1BB, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.Type: ApplicationFiled: September 9, 2011Publication date: September 20, 2012Applicant: PFIZER INCInventors: Bianca AHRENS, Sangita M. BAXI, Timothy Scott FISHER, Richard Michael JEROME, Kathrin LADETZKI-BAEHS, Theodore OLIPHANT, Leslie Lynne SHARP, Michael TESAR, Libbey Anne YATES, Moritz ZULLEY